Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Six month visual quality outcome after implantation of AT LISA tri 839MP trifocal intraocular lenses

Poster Details

First Author: J.Mendicute SPAIN

Co Author(s):    J. Mendicute   L. Bascaran   B. Macias-Murelaga   N. Goñi   D. Coello  

Abstract Details


To determine whether visual quality outcome is as expected with trifocal (AT LISA tri 839 MP) intraocular lenses. To study and analyze quality of vision (OQAS) and quality of life questionnaires after trifocal intraocular lens implantation.


Hospital Universitario Donostia, San Sebastian (SPAIN)


Prospective clinical study. 20 cataractous eyes of 10 patients underwent cataract surgery and trifocal intraocular lens (IOL) implantation. Optical Quality Analysis System (OQAS) measurements and quality of life questionnaires were performed preoperatively, 1 month, 3 months and 6 months after surgery.


Six months after surgery, mean MTF and OSI results were 33.85ḟ10.81 and 1.47ḟ0.46 respectively. All patients reported spectacle independence at all distances, performing all daily activities under any lighting condition. None of the patients who reported one of the following visual effects considered it disturbing or important: 50% of patients reported halos, 30% star lights, 20% hazy or blurry vision, distortion or glare. 10% had visual distortion, momentary focusing difficulty or for depth perception. No patient reported visual fluctuation or diplopia.


OQAS quality of vision assessment was, in our series, at the highest standard and the patients’ subjective visual quality perception is in accordance to objective results recorded. The AT LISA tri 839 MP trifocal lens improves intermediate vision and provides spectacle freedom at all distances in any light condition (including intermediate vision). All of our patients would undergo cataract surgery with implantation of the AT LISA tri 839 MP IOL again.

Financial Disclosure:

... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous